Targeting The Tongue: Helius Medical’s Unique Approach To Neuromodulation Tested In Trials
Neuromodulation start-up Helius Medical Technologies is employing a simpler, more primal connection to send potentially therapeutic signals to the brain – the tongue. The company is entering pivotal clinical trials to test the technology in select patients with traumatic balance disorder and traumatic brain injury, and evaluating the device for use in patients with multiple sclerosis.
You may also be interested in...
Helius Medical announced on April 10 that the US FDA has declined its de novo application for treating brain injury with its Portable Neuromodulation Stimulator.
In recent years, medtech start-ups have made great strides in developing technologies to treat eye disease such as cataracts, diminishing vision, and even dry eye. But the greatest leaps – or the most life changing – may have been executed by companies such as Second Sight Medical Products Inc. and Wicab Inc. that are finding ways to actually help blind people see.
Emerging technologies in peripheral nerve stimulation are expected to play a pivotal role in opening up new markets and driving growth in the neuromodulation device market in the years ahead. As a result, the pipeline is rich with products designed to address a growing number of patients with long-term pain and other chronic conditions, many of whom have no other treatment options.